RESUMEN
Low dose to very high dose aspirin is used to prevent heart attack. We have developed and validated a sensitive and robust method that could detect low levels of aspirin and salicylic acid in plasma and also a novel sample collection procedure to carry out sample preparation at room temperature. The total run time was 3.00 min; the developed method was validated in human plasma with a lower limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic acid. A linear response function was established for the range of concentrations 0.99-756.20 ng/mL (r > 0.998) for aspirin and 2.01-2486.86 ng/mL for salicylic acid. The intra- and inter-day precision values for aspirin and salicylic acid met the acceptance as per FDA guidelines. The developed assay method was applied to an oral pharmacokinetic study in humans.
Asunto(s)
Aspirina/administración & dosificación , Aspirina/farmacocinética , Administración Oral , Aspirina/sangre , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Humanos , Límite de Detección , Masculino , Reproducibilidad de los Resultados , Ácido Salicílico/sangre , Ácido Salicílico/farmacocinética , Espectrometría de Masas en TándemRESUMEN
A robust, specific and fully validated LC-MS/MS method as per general practices of industry has been developed for estimation of lacidipine (LAC) with 100 µL of human plasma using lacidipine-(13) C8 as an internal standard (IS). The API-4000 LC-MS/MS was operated under the multiple reaction-monitoring mode. A simple liquid-liquid extraction process was used to extract LAC and IS from human plasma. The total run time was 3.0 min and the elution of LAC and IS occurred at 1.96 and 1.97 min; this was achieved with a mobile phase consisting of 5 mm ammonium acetate buffer-acetontrile (15:85 v/v) at a flow rate of 0.60 mL/min on a Zorbax SB C18 (50 × 4.6 mm, 5 µm) column. A linear response function was established for the range of concentrations 50-15,000 pg/mL (r > 0.998) for LAC. The current developed method has negligible matrix effect and is free from unwanted adducts and clusters which are formed owing to system such as solvent or mobile phase. The developed assay method was applied to an oral pharmacokinetic study in humans and successfully characterized the pharmacokinetic data up to 72 h.